Formycon AG (FYB)
Deutsche Börse Xetra · Germany · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 18.88 |
|---|---|
| 52-week range | 15.80 – 26.95 |
| Return, 1 month / 3 months | −2.6% / +0.3% |
| Return, 1 year / 3 years | −17.4% / −65.2% |
| Trend | Below its 200-day average |
| RSI (14) | 46 |
| Volatility (1 year) | 52.1% |
| Worst drawdown (1 year) | -35.6% |
| Average daily value traded | 0.08M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Formycon AG is a German biopharmaceutical company that develops biosimilar medicines, which are follow-on versions of complex biologic drugs. It works on copies of biologic treatments used in areas such as eye disease and inflammatory conditions, handling development and manufacturing together with partners. The company is based in Martinsried, near Munich, and its customers are mainly pharmaceutical partners and healthcare markets that use these medicines.
Formycon AG trades under the code FYB on the Deutsche Börse Xetra in Germany, with its price quoted in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Formycon AG (FYB) trades on the Deutsche Börse Xetra in Germany. It last closed at EUR 18.88 on 27 October 2026.
Its price-based Market X-Ray is 41 out of 100 (a weak price profile), ranking 478 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 17.4% and over the last three months it rose 0.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Deutsche Börse Xetra
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 42 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -4.9% | ||
| From 52-week high | -27.7% | ||
| Momentum | 51 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 0.3% | ||
| 6-month return | 5.4% | ||
| 12-month return, skipping the last month | -15.2% | ||
| Stability (higher is calmer) | 30 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 52.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -35.6% | ||
| Liquidity | 42 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.08M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −0.7% |
|---|---|
| 1 month | −2.6% |
| 3 months | +0.3% |
| 6 months | +5.4% |
| 1 year | −17.4% |
| 3 years | −65.2% |
| 5 years | −64.1% |
Signals
| 50-day / 200-day average | 19.56 / 19.85 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.76 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Deutsche Börse Xetra; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.